louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01355757: Post-Operative Quality of Life Evaluation for Different Anesthesia Techniques for Arthroscopic Shoulder Surgery
Official title: Post-Operative Quality of Life Evaluation for Different Anesthesia Techniques for Arthroscopic Shoulder Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Rotator Cuff Injury
Keywords: shoulder arthroscopy
24-week follow-up
quality of life
rehabilitation achievement
rotator cuff repair
Lead sponsor: St. Luke's-Roosevelt Hospital Center
Sponsor class: OTHER
Collaborators: name: Baxter Healthcare Corporation
First posted: 2011-05-18
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Randomized controlled trial on efficacy of single injection or continuous interscalene brachial plexus block on analgesia in patients having outpatient rotator cuff surgery.


Eligibility criteria: Inclusion Criteria:

Patients who agree to participate in the study will be asked to sign the informed consent and the HIPAA form.

Inclusive criteria are:

* 18-75 years of age
* ASA physical status I-III
* BMI \< 35 kg/m2

Exclusion Criteria:

* all open shoulder procedures
* patient having difficulty understanding the instruction on using the anesthetic infusion pump
* contraindications to administration of regional anesthesia (e.g., allergy to a local anesthetic, local infection and coagulopathy)
* significant neurologic disorders of the upper extremity
* psychiatric or cognitive disorders
* history of substance abuse or chronic opioid use

Primary outcomes:
measure: Quality of Life
timeFrame: 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: St. Luke's-Roosevelt Hospital
state: New York
Study officials:
affiliation: St. Luke's-Roosevelt Hospital Center
name: Admir Hadzic, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03655457: Evaluation of the Efficacy of Surfaktant in Preterm Infants by Lung Ultrasound
Official title: Evaluation of the Efficacy of Different Surfactant Preparations in Preterm Infants by Lung Ultrasound
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Lung Ultrasound Scores
Keywords: Lung
RDS
Surfaktant
Lead sponsor: Zekai Tahir Burak Women's Health Research and Education Hospital
Sponsor class: OTHER
First posted: 2018-08-31
Enrollment: 64
Sex: ALL
Minimum age (years): 1
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: To compare the lung ultrasound scores after two different natural surfactant administration as a parameter reflecting lung inflation. Poractant alfa decreases lung ultrasound scores as efficient as beractant treatment

Detailed description: Outcomes:

Improvement of Lung usg scores after surfactanct and the difference between groups at different time points (2nd and 6hr).

Secondary outcome:

The correlation between lung usg scores and clinical scores (silverman scores), FiO2 and PCO2 levels, failure of weaning to noninvasive ventilation after surfactant Preterm infants of 32 gestational weeks and below, who admit to the NICU with signs of respiratory distress, treated with non invasive or mechanical ventilation and require surfactant treatment in 6 hours of life will be enrolled.

Eligibility criteria: Inclusion Criteria:

* Preterm infants of 32 gestational weeks and below, who admit to the NICU with signs of respiratory distress, treated with non invasive or mechanical ventilation and require surfactant treatment in 6 hours of life will be enrolled.

Exclusion Criteria:

* major congenital anomalies.

Primary outcomes:
measure: Lung usg scores
timeFrame: first days
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Zekai Tahir Burak Matarnity Teaching
Study officials:
affiliation: zekai tahir burak matarnity teaching hospital
name: Evrim Alyamaç Dizdar, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03538457: Bariatric Surgery and Pharmacokinetics of Paracetamol
Official title: Bariatric Surgery and Pharmacokinetics of Paracetamol: BAR-MEDS Paracetamol
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Obesity, Morbid
Keywords: Bariatric surgery
Gastrointestinal tract
Biological availability
Pharmacokinetics
Acetaminophen
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
Collaborators: name: St. Olavs Hospital
name: Volvat Medisinsk Senter Stokkan
name: Namsos Hospital
name: Alesund Hospital
First posted: 2018-05-29
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients referred for bariatric surgery (gastric bypass or sleeve gastrectomy)

Brief summary: Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on paracetamol are investigated.


Eligibility criteria: Inclusion Criteria:

* Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway
* Being a Norwegian citizen

Exclusion Criteria:

* Having previously undergone resections in the GI-tract

Primary outcomes:
measure: Paracetamol concentration in blood serum (area under curve (AUC))
timeFrame: From baseline to 1 year postoperatively
Secondary outcomes:
Other outcomes:
Locations:
city: Trondheim
country: Norway
facility: St. Olavs University Hospital
Study officials:
affiliation: St. Olavs University Hospital
name: Magnus Strømmen, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06757257: Special Drug Use-results Survey for Long-term Use (Fostamatinib)
Official title: Special Drug Use-results Survey for Long-term Use (Fostamatinib)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Chronic Idiopathic Thrombocytopenic Purpura
Lead sponsor: Kissei Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2025-01-03
Enrollment: 149
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with chronic idiopathic thrombocytopenic purpura who are treatment with fostamatinib for the first time.

Brief summary: The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.

Detailed description: The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.

Eligibility criteria: Inclusion Criteria:

* Patients with chronic idiopathic thrombocytopenic purpura who are treatment with fostamatinib for the first time.

Primary outcomes:
measure: Adverse events
timeFrame: 18 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tokyo And Japanese Other Cities
country: Japan
facility: Research site
Study officials:
References:
Clinical trial NCT06328257: Impact of Myofascial Release on Preventing Dysphagia in the Elderly Community
Official title: Effect of Myofascial Release on Dysphagia Prevention for Elderly People in the Community: A Preliminary Self-control Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Dysphagia
Lead sponsor: Chao Phya Abhaibhubejhr Hospital
Sponsor class: OTHER_GOV
First posted: 2024-03-25
Enrollment: 300
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The goal of this clinical trial is to explore the impact of Myofascial Release Training on swallowing function and quality of life in community-dwelling elderly individuals (≥60 year old) with swallowing disorders. It primarily aims to address the effects of Myofascial Release Training on swallowing function and quality of life in community-dwelling elderly individuals with swallowing disorders. All participants are required to undergo a continuous three-week (21 days) Myofascial Release Training, with weekends off and training conducted only on weekdays. The training will be conducted two sessions per day, lasting 15-30 minutes each.

Detailed description: Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation.

The goal of this clinical trial is to explore the impact of Myofascial Release Training on swallowing function and quality of life in community-dwelling elderly individuals (≥60 year old) with swallowing disorders. It primarily aims to address the effects of Myofascial Release Training on swallowing function and quality of life in community-dwelling elderly individuals with swallowing disorders. All participants are required to undergo a continuous three-week (21 days) Myofascial Release Training, with weekends off and training conducted only on weekdays. The training will be conducted two sessions per day, lasting 15-30 minutes each.

Eligibility criteria: Inclusion Criteria:

* Age over 60 years old.
* No hospitalization within the past six months.
* With clear consciousness and able to cooperate with questionnaires and training.
* The elderly people who voluntarily participate and agree to adhere until the end of the study.
* Dysphagia

Exclusion Criteria:

* Complicated with severe liver and kidney failure, tumors, or hematological disorders.
* Physical disability.
* Difficulty in mobility.

Primary outcomes:
measure: Swallowing-Related Quality of Life Questionnaire
timeFrame: day 1 and day 21
Secondary outcomes:
measure: Time consumed in eating
timeFrame: day 1 and day 21
measure: Functional Oral Intake Scale
timeFrame: day 1 and day 21
Other outcomes:
Locations:
Study officials:
affiliation: Site Coordinator of United Medical Group
name: Nieto Luis
role: STUDY_CHAIR
References:
Clinical trial NCT04048057: The Effect of Different Exercise Programs in Coronary Artery Patients: A Randomized Controlled Study
Official title: The Effect of Different Exercise Programs in Coronary Artery Patients: A Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Exercise
Cardiac Rehabilitation
Lead sponsor: Kutahya Health Sciences University
Sponsor class: OTHER
First posted: 2019-08-07
Enrollment: 20
Sex: ALL
Minimum age (years): 30
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: There are studies showing the superiority of HIIT protocols in patients with CAD in the literature, however there is no consensus on the use of HIIT protocols in CAD patients. In addition, in these studies, the HIIT protocols differ in severity and duration and there is no optimal HIIT protocol. Therefore, this study was planed to investigate of two different HIIT protocols and one MICT protocols, which are more commonly used in patients with CAD in the literature on exercise capacity, quality of life, body composition, physical activity level and fear of movement.


Eligibility criteria: Inclusion Criteria:

* Have undergone percutaneous transluminal coronary angioplasty or coronary artery bypass graft surgery,
* Nonobstructive CAD registered by angiography
* Left ventricular ejection fraction above 50%,
* Clinically stable for more than 2 weeks in terms of symptoms and medical treatment.

Exclusion Criteria:

* Ischemia symptoms,
* Being in Class III-IV according to the New York Heart Classification,
* Obtaining significant left ventricular outflow obstruction,
* Ventricular arrhythmia,
* Being marked valvular heart disease,
* Failure to comply with exercise testing and training rules,
* To have significant orthopedic or neurological comorbidity that prevents full participation.

Primary outcomes:
measure: exercise capacity
timeFrame: 15 minutes
Secondary outcomes:
measure: MacNew Health Related Quallity of Life Qustionnaire
timeFrame: 15 minutes
measure: body composition
timeFrame: 1 minute
measure: physical activity level
timeFrame: 15 minutes
measure: fear of movement
timeFrame: 15 minutes
Other outcomes:
Locations:
city: Kutahya
country: Turkey
facility: Kutahya Health Sciences University
state: Center
Study officials:
References:
Clinical trial NCT00011557: Functional Magnetic Micturition in Patients w/SCI
Official title: Functional Magnetic Micturition in Patients w/SCI
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Spinal Cord Injury
Keywords: Bladder, electromagnetic fields, Spinal cord injury
Lead sponsor: VA Office of Research and Development
Sponsor class: FED
First posted: 2001-02-26
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This project will determine the ultimate usefulness of functional magnetic stimulation (FMS) as an assistive device for voiding in patients with SCI.

Detailed description: Investigators intend to determine the ultimate usefulness of functional magnetic stimulation (FMS) as an assistive device for voiding in patients with SCI.

Thirty six persons will be recruited and will undergo an 8 week protocol for conditioning of the bladder. The investigators propose to: investigate the changes in bladder function in response to long-term bladder conditioning by FMS; further optimize the FMS technology and parameters for effective bladder emptying in SCI; evaluate the role of the external sphincter muscle fatigue by FS in facilitating bladder emptying; critically evaluate the relative response of FMS data to existing information using functional electrical stimulation;further develop criteria that will be used to predict which SCI patients are optimally suitable for FMS; establish a comprehensive stimulation criteria that will reflect the safety and effectiveness of structures associated with the bladder that are exposed to the electro-myographic field.

Eligibility criteria: Patients with SCI above T10 level, six months post injury

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Long Beach
country: United States
facility: VAMC, Long Beach
state: California
Study officials:
affiliation: Program Analysis and Review Section (PARS), Rehabilitation Research & Development Service
name: John Fryer, Ph.D. Asst. Director
affiliation: Program Analysis and Review Section (PARS), Rehabilitation Research & Development Service
name: Nancy Rocheleau, Program Analyst
References:
Clinical trial NCT01483157: Vascular Occlusion and Rheumatoid Arthritis
Official title: Effects of Strength Training With Vascular Occlusion in Patients With Rheumatoid Arthritis: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Rheumatoid Arthritis
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2011-12-01
Enrollment: 30
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Resistance exercise plus vascular occlusion may induce greater improvements in strength and muscle mass resistance training alone. The investigators speculate this training strategy could be beneficial in patients with rheumatoid arthritis.


Eligibility criteria: Inclusion Criteria:

* female with rheumatoid arthritis
* Disease activity scores \> 2.6
* use of anti-TNF-alpha drugs for at least 8 weeks

Exclusion Criteria:

* BMD \< 20 kg/m2
* fibromyalgia
* cardiovascular disease

Primary outcomes:
measure: muscle strength
timeFrame: twelve weeks
Secondary outcomes:
measure: quality of life
timeFrame: twelve weeks
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: University of Sao Paulo - School of Medicine - Clinical Hospital
Study officials:
References:
citation: Rodrigues R, Ferraz RB, Kurimori CO, Guedes LK, Lima FR, de Sa-Pinto AL, Gualano B, Roschel H. Low-Load Resistance Training With Blood-Flow Restriction in Relation to Muscle Function, Mass, and Functionality in Women With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2020 Jun;72(6):787-797. doi: 10.1002/acr.23911. Epub 2020 May 14.
Clinical trial NCT05710757: Investigating Proximal Muscle Strength Effects by Incorporating Proximal Muscle Lengthening
Official title: Investigating Proximal Muscle Strength Effects by Incorporating Proximal Muscle Lengthening
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Proximal Muscle Strength
Proximal Muscle Lengthening
Keywords: blood flow restriction
myofascial release
Lead sponsor: University of Tennessee
Sponsor class: OTHER
First posted: 2023-02-02
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The control group will receive a sham myofascial release pectoralis minor release intervention. The experimental group will receive a myofascial release pectoralis minor release intervention. Both groups will receive blood flow restriction exercise to strength the scapula retractors.
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess strength gains of proximal musculature in the nondominant upper extremity after implementing blood flow restriction (BFR) and myofascial release (MFR) with the supplementation of whey protein.

Detailed description: The purpose of this study is to assess strength gains of proximal musculature in the nondominant upper extremity after implementing blood flow restriction (BFR) and myofascial release (MFR) with the supplementation of whey protein. Blood flow restricted (BFR) exercise is the brief and non-continuous blockage of venous blood flow using a device that restricts the flow of blood while exercising. This technique is used to produce hypertrophy (muscle growth) and strength responses while exercising at a lighter load than traditionally required to produce a similar response. Myofascial release (MFR) is a technique that involves applying gentle sustained pressure into the myofascial connective tissue restrictions to eliminate pain and restore motion.

Eligibility criteria: Inclusion Criteria:

* Healthy individuals between the age of 18 and 30

Exclusion Criteria:

* Individuals with uncontrolled high blood pressure
* Individuals with sickle cell anemia, current pregnancy
* Individuals with a history of deep vein thrombosis
* Individuals with diabetes
* Individuals with active infection
* Individuals with less than normal range of motion or muscle strength
* Individuals with moderate to severe upper extremity injury in the past 12 months
* Individuals with a current diagnosis of cancer.

Primary outcomes:
measure: Scapular retraction strength
timeFrame: 8 weeks
Secondary outcomes:
measure: One repetition maximum (1RM)
timeFrame: 8 weeks
Other outcomes:
measure: Length for the pectoralis minor
timeFrame: 8 weeks
Locations:
city: Memphis
country: United States
facility: University of Tennessee Health Science Center
state: Tennessee
Study officials:
References:
Clinical trial NCT01232257: Effect of N-acetylcysteine (NAC) on Hydrogen Sulfide (H2S) in Chronic Kidney Disease (CKD)
Official title: Effect of N-acetylcysteine on Hydrogen Sulfide in Chronic Kidney Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Chronic Kidney Disease
Chronic Kidney Failure
End Stage Kidney Disease
End Stage Renal Disease
Keywords: Chronic kidney disease
Chronic kidney failure
End stage kidney disease
End stage renal disease
Hydrogen sulfide
N-acetylcysteine
Acetylcysteine
Lead sponsor: UMC Utrecht
Sponsor class: OTHER
First posted: 2010-11-02
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Cardiovascular morbidity and mortality is high in CKD patients. Nitric oxide (NO) deficiency plays a crucial role in progression of CKD. This leads to endothelial dysfunction, hypertension, and inflammation. Hydrogen sulfide (H2S) could serve as a backup mechanism for NO deficiency in CKD. N-acetylcysteine (NAC) is a derivate of cysteine and this is the main substrate for H2S production. Therefore, NAC should enable us to stimulate H2S production in humans. Our objective is to investigate the effect of NAC on plasma H2S levels and on markers of oxidative stress, inflammation, and endothelial dysfunction in healthy volunteers, CKD patients, and dialysis patients. We hypothesize that there is an increase in H2S levels after treatment with NAC.


Eligibility criteria: Inclusion criteria:

Healthy volunteers:

* Adult (\> 18 years and older)
* Healthy, as assessed by medical history, blood pressure, plasma creatinine, and urine dipstick
* No medication use

CKD patient:

* Adult (\> 18 years and older)
* CKD stage 3-4 (GFR 15-60 ml/min)

Hemodialysis patient:

* Adult (\> 18 years and older)
* Hemodialysis patient

Peritoneal dialysis patient:

* Adult (\> 18 years and older)
* Peritoneal dialysis patient

Exclusion criteria:

* Unable to give informed consent
* Hypersensitivity to N-acetylcysteine
* Pregnancy

Primary outcomes:
measure: Hydrogen sulfide (H2S)
timeFrame: After 48 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Utrecht
country: Netherlands
facility: UMC Utrecht
Study officials:
affiliation: UMC Utrecht
name: M C Verhaar, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: UMC Utrecht
name: A C Abrahams, MD
role: PRINCIPAL_INVESTIGATOR
References: